MÖLNDAL, Sweden, May 5, 2025 /PRNewswire/ -- Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces the appointment of Martin Hillsten as the new CEO, effective immediately. He succeeds acting CEO Scott Flora, who will continue to support US marketing activities in an advisory capacity and remain on the company's Board of Directors. Martin Hillsten most recently served as CEO of Integration Diagnostics and has extensive experience in the sales and marketing of advanced medical devices in the US and other parts of the world.

MÖLNDAL, Sweden, March 18, 2025 /PRNewswire/ -- Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) announces today that a newly published independent study from the Walter Reed National Military Medical Center in Bethesda, Maryland, U.S., provides compelling evidence of OPRA™ Implant System's treatment effectiveness in transfemoral amputees. The study demonstrates significant functional improvements over traditional socket prostheses, an important validation of Integrum's innovative technology and its clinical benefit in patients who have undergone amputation.

MÖLNDAL, Sweden, Jan. 28, 2025 /PRNewswire/ -- Integrum, (STO: INTEG) , the leader in innovative bone-anchored prosthetic solutions, is proud to announce the expansion of their 2025 Education Calendar. In collaboration with Southern Prosthetic Supply (SPS), the leading U.S. distributor of orthotic and prosthetic (O&P) products, and other leading prosthetic manufacturers, Integrum will co-host seven regional educational events across the United States in the coming months. These events will provide prosthetists with knowledge of the OPRA™ Implant System and how it integrates into their clinical practices to provide a solution for their transfemoral amputee patients who struggle with or are expected to struggle with the use of traditional sockets.

MÖLNDAL, Sweden, Jan. 15, 2025 /PRNewswire/ -- Integrum AB (publ), ticker (STO: INTEG), the medical technology company that provides the bone-anchored OPRA® Implant System to amputees, partners with Intelerad to Streamline Surgical Planning and Enhance Patient Outcomes

As part of its commitment to innovation and patient care, Integrum provides custom surgical templates to its surgeon partners. These templates are tailored to each patient using three-dimensional (3D) CT scans of the patient's bone structure, based on Integrum's protocol. This meticulous process helps surgeons to ensure an optimal implant fit, ultimately leading to better outcomes for patients.

MÖLNDAL, Sweden, Nov. 28, 2024 /PRNewswire/ -- Integrum AB (publ), ticker (STO: INTEG), a leader in medical technology and developer of the bone-anchored OPRA® Implant System, announces the launch of a new service initiative to enhance warranty and service support for its Axor™ II devices. This initiative is a critical step in advancing Integrum's expansion in the U.S. market and driving sustainable growth.

The new program focuses on significantly reducing service turnaround times and delivering a streamlined, efficient customer experience for Axor™ II devices in the U.S. With this initiative, Integrum aims to provide unmatched support to clinicians and amputees, ensuring continuity of care and optimal device performance.